Egetis Therapeutics AB Share Price
Stocks
EGTX
SE0003815604
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq Stockholm
10:30:00 10/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 11.10 SEK | -0.18% |
|
+11.67% | +107.87% |
| 09/11 | Stockholm exchange rises slightly at open, Qliro surges on bid | FW |
| 09/11 | Stockholm bourse set to open slightly lower | FW |
| Market Cap | 516.11Cr 52Cr 47Cr 43Cr 39Cr 74Cr 4.89TCr 76Cr 205.63Cr 2.62TCr 195.73Cr 191.58Cr 8.28TCr | P/E 2026 * |
131x | P/E 2027 * | -42.9x |
|---|---|---|---|---|---|
| Enterprise Value | 422.91Cr 43Cr 38Cr 35Cr 32Cr 61Cr 4.01TCr 62Cr 168.5Cr 2.15TCr 160.38Cr 156.98Cr 6.79TCr | EV / Sales 2026 * |
37.4x | EV / Sales 2027 * | 8.67x |
| Free-Float |
37.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| EGTX | Delayed | |
London S.E.
| 0ABW | Delayed | |
|
CBOE
| Real-time | ||
|
OTC Markets
| PDPHF | Delayed | |
|
Boerse Muenchen
| P0F | Real-time | |
|
Börse Stuttgart
| P0F | Delayed | |
|
Deutsche Boerse AG
| P0F | Delayed | |
|
CBOE
| 0ABW | Real-time |
Last Transcript: Egetis Therapeutics AB
| 1 day | -0.18% | ||
| 1 week | +11.67% | ||
| Current month | +10.34% | ||
| 1 month | +11.78% | ||
| 3 months | +58.80% | ||
| 6 months | +71.30% | ||
| Current year | +107.87% |
| 1 week | 11.06 |  | 11.16 |
| 1 month | 8.96 | | 11.16 |
| Current year | 4.23 | | 11.16 |
| 1 year | 3.62 | | 11.16 |
| 3 years | 3.02 | | 11.16 |
| 5 years | 3 | | 11.16 |
| 10 years | 3 | | 22.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 16/06/2017 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 47 | 31/12/2017 |
Tiago Nune
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 01/01/2017 | |
Mats Blom
CHM | Chairman | 61 | 06/05/2024 |
Behshad Sheldon
BRD | Director/Board Member | 63 | 01/01/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 02/09/26 | Sell | Executive/Senior Manager | -594 | 0.0001% | ||
| 31/08/26 | Exercice | Chief Financial Officer | 1,099 | 0.0002% | ||
| 31/08/26 | Buy | Chief Operating Officer | 1,099 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18% | +11.67% | +79.90% | +117.22% | 52Cr | |
| +0.01% | +11.10% | +60.83% | +70.43% | 6.83TCr | |
| +1.22% | +9.56% | +15.97% | +90.23% | 6.03TCr | |
| +0.24% | +1.35% | +23.78% | +97.55% | 5.59TCr | |
| +1.60% | +19.44% | +28.80% | +112.95% | 4.84TCr | |
| -1.32% | +4.78% | +29.15% | +40.40% | 4.53TCr | |
| -3.54% | -0.60% | +207.76% | +879.50% | 4.18TCr | |
| -3.33% | +6.90% | +22.78% | +48.07% | 3.45TCr | |
| -2.19% | -3.71% | +90.94% | +66.33% | 3.38TCr | |
| -1.77% | +0.83% | +46.57% | -0.16% | 2.6TCr | |
| Average | -0.93% | +6.02% | +60.65% | +152.25% | 4TCr | |
| Weighted average by Cap. | -0.67% | +5.26% | +55.33% | +153.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 11Cr 1.14Cr 1.02Cr 94.33L 85.67L 1.62Cr 107.01Cr 1.67Cr 4.5Cr 57Cr 4.28Cr 4.19Cr 181.25Cr | 51Cr 5.17Cr 4.64Cr 4.28Cr 3.88Cr 7.35Cr 485.07Cr 7.55Cr 20Cr 259.88Cr 19Cr 19Cr 821.56Cr |
| Net income | 41Cr 4.18Cr 3.75Cr 3.46Cr 3.14Cr 5.94Cr 392.24Cr 6.11Cr 16Cr 210.15Cr 16Cr 15Cr 664.34Cr | -4.26Cr -43.07L -38.62L -35.6L -32.33L -61.18L -40Cr -62.89L -1.7Cr -22Cr -1.62Cr -1.58Cr -68Cr |
| Net Debt | -93Cr -9.42Cr -8.45Cr -7.78Cr -7.07Cr -13Cr -883.02Cr -14Cr -37Cr -473.09Cr -35Cr -35Cr -1.5TCr | -72Cr -7.28Cr -6.53Cr -6.01Cr -5.46Cr -10Cr -682.22Cr -11Cr -29Cr -365.51Cr -27Cr -27Cr -1.16TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/26/10 | SEK 11.10 | -0.18% | 47,22,428 |
| 09/26/09 | SEK 11.12 | 0.00% | 45,71,816 |
| 06/26/06 | SEK 11.12 | 0.00% | 87,94,096 |
| 05/26/05 | SEK 11.12 | +11.31% | 3,33,32,869 |
| 04/26/04 | SEK 9.990 | +0.50% | 47,46,802 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- EGTX Stock
Select your edition
All financial news and data tailored to specific country editions
